Abstract
Safety and effectiveness of COVID-19 vaccines during pregnancy is a particular concern affecting vaccination uptake by this vulnerable group. Here we evaluated evidence from 23 studies including 117,552 COVID-19 vaccinated pregnant people, almost exclusively with mRNA vaccines. We show that the effectiveness of mRNA vaccination against RT-PCR confirmed SARS-CoV-2 infection 7 days after second dose was 89·5% (95% CI 69·0-96·4%, 18,828 vaccinated pregnant people, I2 = 73·9%). The risk of stillbirth was significantly lower in the vaccinated cohort by 15% (pooled OR 0·85; 95% CI 0·73–0·99, 66,067 vaccinated vs. 424,624 unvaccinated, I2 = 93·9%). There was no evidence of a higher risk of adverse outcomes including miscarriage, earlier gestation at birth, placental abruption, pulmonary embolism, postpartum haemorrhage, maternal death, intensive care unit admission, lower birthweight Z-score, or neonatal intensive care unit admission (p > 0.05 for all). COVID-19 mRNA vaccination in pregnancy appears to be safe and is associated with a reduction in stillbirth.
【초록키워드】 COVID-19, mRNA vaccination, COVID-19 vaccine, vaccination, Safety, intensive care, SARS-COV-2 infection, risk, RT-PCR, mRNA vaccines, adverse outcome, Cohort, Pregnancy, Stillbirth, Effectiveness, death, placental, Admission, Evidence, pregnant, Neonatal, Safe, COVID-19 mRNA Vaccination, gestation, higher risk, 95% CI, second dose, Z-score, significantly lower, evaluated, appear, reduction in, affecting, 【제목키워드】 Meta-analysis, outcome, Pregnancy, COVID-19 vaccination, Effectiveness,